These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31477251)

  • 1. Erythropoiesis-Stimulating Agents and Cancer: Myth or Truth.
    Choi MJ; Yee J
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):221-224. PubMed ID: 31477251
    [No Abstract]   [Full Text] [Related]  

  • 2. Erythropoiesis-stimulating agents on trial: are higher dosages causing harm?
    Chaknos CM; Berns JS
    Am J Kidney Dis; 2013 Jan; 61(1):6-8. PubMed ID: 23245737
    [No Abstract]   [Full Text] [Related]  

  • 3. Erythropoiesis-stimulating agents--time for a reevaluation.
    Unger EF; Thompson AM; Blank MJ; Temple R
    N Engl J Med; 2010 Jan; 362(3):189-92. PubMed ID: 20054037
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer.
    Hazzan AD; Shah HH; Hong S; Sakhiya V; Wanchoo R; Fishbane S
    Kidney Int; 2014 Jul; 86(1):34-9. PubMed ID: 24402094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to "Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia".
    Littlewood TJ
    Oncologist; 2007 Aug; 12(8):1031-2; author reply 1032-4. PubMed ID: 17766663
    [No Abstract]   [Full Text] [Related]  

  • 6. [Use of erythropoiesis stimulating agents].
    Abreu PF; Romão Junior JE; Bastos MG
    J Bras Nefrol; 2014 Mar; 36(1 Suppl 1):19-23. PubMed ID: 24770599
    [No Abstract]   [Full Text] [Related]  

  • 7. Is it safe to use erythropoiesis-stimulating agents to treat anemia in chronic kidney disease patients with active malignancies?
    Gupta G; Choi MJ
    Semin Dial; 2011; 24(4):379-81. PubMed ID: 21801225
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety of erythropoiesis-stimulating agents in patients with end-stage kidney disease: data are safer than extrapolations.
    Abraham I; MacDonald K
    Expert Opin Drug Saf; 2012 Nov; 11(6):885-7. PubMed ID: 22998694
    [No Abstract]   [Full Text] [Related]  

  • 9. Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia.
    Lappin TR; Maxwell AP; Johnston PG
    Oncologist; 2007 Apr; 12(4):362-5. PubMed ID: 17470677
    [No Abstract]   [Full Text] [Related]  

  • 10. Anemia of chronic kidney disease: Treat it, but not too aggressively.
    Nakhoul G; Simon JF
    Cleve Clin J Med; 2016 Aug; 83(8):613-24. PubMed ID: 27505883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Drug Saf; 2012 Nov; 11(6):923-31. PubMed ID: 22916722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of Physiological Erythropoiesis in the Treatment of Chronic Kidney Disease-Associated Anemia.
    Kuragano T; Nakanishi T
    Contrib Nephrol; 2018; 196():52-57. PubMed ID: 30041204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoiesis-stimulating agents for anaemia in chronic kidney disease: Are they all the same?
    Mudge D; Webster A
    Cochrane Database Syst Rev; 2014 Dec; 2014(12):ED000093. PubMed ID: 25549989
    [No Abstract]   [Full Text] [Related]  

  • 14. Lost without directions: lessons from the anemia debate and the drive study.
    Spiegel DM; Chertow GM
    Clin J Am Soc Nephrol; 2009 May; 4(5):1009-10. PubMed ID: 19357246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug safety profile of darbepoetin alfa for anemia of chronic kidney disease.
    Agarwal AK
    Expert Opin Drug Saf; 2009 Mar; 8(2):145-53. PubMed ID: 19309243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anemia Treatment After 30 Years of Erythropoietic Stimulating Agents: No Longer Business as Usual?
    Wish JB
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):225-228. PubMed ID: 31477252
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel Masters of Erythropoiesis: Hypoxia Inducible Factors and Recent Advances in Anemia of Renal Disease.
    Solak Y; Cetiner M; Siriopol D; Tarim K; Afsar B; Covic A; Kanbay M
    Blood Purif; 2016; 42(2):160-7. PubMed ID: 27318465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease.
    Robles NR
    Clin Drug Investig; 2016 Jun; 36(6):421-31. PubMed ID: 26894799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Erythropoietin stimulating agents in chronic kidney disease: indications and contraindications].
    Żebrowski P; Mieczkowski M
    Wiad Lek; 2016; 69(5):753-755. PubMed ID: 28033602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoiesis-stimulating agents (ESAs), from chemotherapy-induced anemia to any cancer-related anemia?
    Venturino A; Colloca G
    Ann Oncol; 2010 Apr; 21(4):905-906. PubMed ID: 20032124
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.